VARIDT 1.0: variability of drug transporter database
暂无分享,去创建一个
Feng Zhu | Su Zeng | Wen Sun | Jiayi Yin | Jiajun Hong | Ying Zhou | Yinjing Lu | Jia Xue | Lushan Yu | S. Zeng | Lushan Yu | Feng Zhu | Jiajun Hong | Fengcheng Li | Feng Cheng Li | Jiayi Yin | Wen Sun | Xiaoxu Li | Ying Zhou | Yinjing Lu | Mengzhi Liu | Xue Zhang | Na Chen | Xiuping Jin | Jia Xue | X. Li | Na Chen | Mengzhi Liu | Xue Zhang | Xiuping Jin | Xiao Xu Li
[1] Sanjay K. Nigam,et al. What do drug transporters really do? , 2014, Nature Reviews Drug Discovery.
[2] K. To,et al. Reversal of platinum drug resistance by the histone deacetylase inhibitor belinostat. , 2017, Lung cancer.
[3] Jun Yan,et al. METscout: a pathfinder exploring the landscape of metabolites, enzymes and transporters , 2012, Nucleic Acids Res..
[4] Huijun Sun,et al. Combination of dihydromyricetin and ondansetron strengthens antiproliferative efficiency of adriamycin in K562/ADR through downregulation of SORCIN: A new strategy of inhibiting P‐glycoprotein , 2018, Journal of cellular physiology.
[5] Benjamin M. Bolstad,et al. affy - analysis of Affymetrix GeneChip data at the probe level , 2004, Bioinform..
[6] M. Schwab,et al. DNA Methylation of ADME Genes , 2016, Clinical pharmacology and therapeutics.
[7] Feng Zhu,et al. Simultaneous Improvement in the Precision, Accuracy, and Robustness of Label-free Proteome Quantification by Optimizing Data Manipulation Chains* , 2019, Molecular & Cellular Proteomics.
[8] Xiaofeng Li,et al. ANPELA: analysis and performance assessment of the label-free quantification workflow for metaproteomic studies , 2019, Briefings Bioinform..
[9] Tingting Fu,et al. Therapeutic target database update 2018: enriched resource for facilitating bench-to-clinic research of targeted therapeutics , 2017, Nucleic Acids Res..
[10] P. Sexton,et al. Drug transporters in drug efficacy and toxicity. , 2012, Annual review of pharmacology and toxicology.
[11] Byunghan Lee,et al. Deep learning in bioinformatics , 2016, Briefings Bioinform..
[12] Alan F. Scott,et al. OMIM.org: leveraging knowledge across phenotype–gene relationships , 2018, Nucleic Acids Res..
[13] Andrew R. Leach,et al. ChEMBL: towards direct deposition of bioassay data , 2018, Nucleic Acids Res..
[14] Andrea Bernini,et al. A Computational Approach From Gene to Structure Analysis of the Human ABCA4 Transporter Involved in Genetic Retinal Diseases. , 2017, Investigative ophthalmology & visual science.
[15] P. Neven,et al. Genetic variability in the multidrug resistance associated protein-1 (ABCC1/MRP1) predicts hematological toxicity in breast cancer patients receiving (neo-)adjuvant chemotherapy with 5-fluorouracil, epirubicin and cyclophosphamide (FEC). , 2013, Annals of oncology : official journal of the European Society for Medical Oncology.
[16] Christoph Steinbeck,et al. ChEBI in 2016: Improved services and an expanding collection of metabolites , 2015, Nucleic Acids Res..
[17] G. Peters,et al. ABCG2 harboring the Gly482 mutation confers high-level resistance to various hydrophilic antifolates. , 2005, Cancer research.
[18] Wenwen Jiang,et al. The Potential Drug–Drug Interactions of Ginkgolide B Mediated by Renal Transporters , 2015, Phytotherapy research : PTR.
[19] S. Zeng,et al. Epigenetic activation of the drug transporter OCT2 sensitizes renal cell carcinoma to oxaliplatin , 2016, Science Translational Medicine.
[20] Tony Tse,et al. ClinicalTrials.gov and Drugs@FDA: A Comparison of Results Reporting for New Drug Approval Trials , 2016, Annals of Internal Medicine.
[21] B. Walker,et al. ABCC1 confers tissue-specific sensitivity to cortisol versus corticosterone: A rationale for safer glucocorticoid replacement therapy , 2016, Science Translational Medicine.
[22] Sean R. Davis,et al. NCBI GEO: archive for functional genomics data sets—update , 2012, Nucleic Acids Res..
[23] Elizabeth M. Smigielski,et al. dbSNP: the NCBI database of genetic variation , 2001, Nucleic Acids Res..
[24] Mei-Juan Tu,et al. RNA therapy: Are we using the right molecules? , 2019, Pharmacology & therapeutics.
[25] B. Li,et al. The SCN1A Mutation Database: Updating Information and Analysis of the Relationships among Genotype, Functional Alteration, and Phenotype , 2015, Human mutation.
[26] Jinxiu Lei,et al. Inhibition of histone deacetylase 7 reverses concentrative nucleoside transporter 2 repression in colorectal cancer by up‐regulating histone acetylation state , 2018, British journal of pharmacology.
[27] A. Yu,et al. Bioengineered miR-27b-3p and miR-328-3p modulate drug metabolism and disposition via the regulation of target ADME gene expression , 2018, Acta pharmaceutica Sinica. B.
[28] Minoru Kanehisa,et al. KEGG: new perspectives on genomes, pathways, diseases and drugs , 2016, Nucleic Acids Res..
[29] L. Loeb,et al. The influence of subclonal resistance mutations on targeted cancer therapy , 2016, Nature Reviews Clinical Oncology.
[30] Deborah A Zarin,et al. How to avoid common problems when using ClinicalTrials.gov in research: 10 issues to consider , 2018, British Medical Journal.
[31] K. Giacomini,et al. SLC transporters as therapeutic targets: emerging opportunities , 2015, Nature Reviews Drug Discovery.
[32] Xing Chen,et al. MicroRNAs and complex diseases: from experimental results to computational models , 2019, Briefings Bioinform..
[33] Ian T. Paulsen,et al. TransportDB 2.0: a database for exploring membrane transporters in sequenced genomes from all domains of life , 2016, Nucleic Acids Res..
[34] K. Brouwer,et al. Disease‐Associated Changes in Drug Transporters May Impact the Pharmacokinetics and/or Toxicity of Drugs: A White Paper From the International Transporter Consortium , 2018, Clinical pharmacology and therapeutics.
[35] P. Borst,et al. N-lactoyl-amino acids are ubiquitous metabolites that originate from CNDP2-mediated reverse proteolysis of lactate and amino acids , 2015, Proceedings of the National Academy of Sciences.
[36] Y. Assaraf,et al. Not only P-glycoprotein: Amplification of the ABCB1-containing chromosome region 7q21 confers multidrug resistance upon cancer cells by coordinated overexpression of an assortment of resistance-related proteins. , 2017, Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy.
[37] Andreas Bender,et al. Metrabase: a cheminformatics and bioinformatics database for small molecule transporter data analysis and (Q)SAR modeling , 2015, Journal of Cheminformatics.
[38] M. Avila,et al. Causes of hOCT1‐Dependent Cholangiocarcinoma Resistance to Sorafenib and Sensitization by Tumor‐Selective Gene Therapy , 2019, Hepatology.
[39] Milton H. Saier,et al. The Transporter Classification Database (TCDB): recent advances , 2015, Nucleic Acids Res..
[40] F Müller,et al. Pharmacokinetic Evaluation of a Drug Transporter Cocktail Consisting of Digoxin, Furosemide, Metformin, and Rosuvastatin , 2016, Clinical pharmacology and therapeutics.
[41] Zhankui Jia,et al. Down-regulation of miR-210-3p encourages chemotherapy resistance of renal cell carcinoma via modulating ABCC1 , 2018, Cell & Bioscience.
[42] S. Zeng,et al. Regulation of OCT2 transcriptional repression by histone acetylation in renal cell carcinoma , 2019, Epigenetics.
[43] Terence P. Speed,et al. A comparison of normalization methods for high density oligonucleotide array data based on variance and bias , 2003, Bioinform..
[44] Feng Xu,et al. Therapeutic target database update 2016: enriched resource for bench to clinical drug target and targeted pathway information , 2015, Nucleic Acids Res..
[45] Wei Wu,et al. The drug transporter OAT3 (SLC22A8) and endogenous metabolite communication via the gut–liver–kidney axis , 2017, The Journal of Biological Chemistry.
[46] Bo Li,et al. NOREVA: normalization and evaluation of MS-based metabolomics data , 2017, Nucleic Acids Res..
[47] Joshua C. Euteneuer,et al. Influence of OCT1 Ontogeny and Genetic Variation on Morphine Disposition in Critically Ill Neonates: Lessons From PBPK Modeling and Clinical Study , 2018, Clinical pharmacology and therapeutics.
[48] Bhagwat Prasad,et al. Interindividual and Regional Variability in Drug Transporter Abundance at the Human Blood–Brain Barrier Measured by Quantitative Targeted Proteomics , 2019, Clinical pharmacology and therapeutics.
[49] O. van Tellingen,et al. Preclinical Mouse Models To Study Human OATP1B1- and OATP1B3-Mediated Drug-Drug Interactions in Vivo. , 2015, Molecular pharmaceutics.
[50] E. Giovannetti,et al. Role of proton-coupled folate transporter in pemetrexed resistance of mesothelioma: clinical evidence and new pharmacological tools , 2017, Annals of oncology : official journal of the European Society for Medical Oncology.
[51] M. Niemi,et al. Membrane transporters in drug development , 2010, Nature Reviews Drug Discovery.
[52] F. Rodieux,et al. Causes and Consequences of Variability in Drug Transporter Activity in Pediatric Drug Therapy , 2016, Journal of clinical pharmacology.
[53] T. Ishikawa,et al. A New Trend in Personalized Medicine: Rapid Detection of SNPs in Drug Transporter Genes by the SmartAmp Method , 2011, Clinical pharmacology and therapeutics.
[54] Alasdair J. G. Gray,et al. The IUPHAR/BPS Guide to PHARMACOLOGY in 2018: updates and expansion to encompass the new guide to IMMUNOPHARMACOLOGY , 2017, Nucleic Acids Res..
[55] Ke Wang,et al. Recent advance in the pharmacogenomics of human Solute Carrier Transporters (SLCs) in drug disposition☆ , 2017, Advanced drug delivery reviews.
[56] C. Allis,et al. Epigenetics: A Landscape Takes Shape , 2007, Cell.
[57] A. Hauschild,et al. Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial , 2012, The Lancet.
[58] Cheng Huang,et al. Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: A review of the past decade. , 2016, Cancer letters.
[59] P. Marquet,et al. Endogenous Metabolites‐Mediated Communication Between OAT1/OAT3 and OATP1B1 May Explain the Association Between SLCO1B1 SNPs and Methotrexate Toxicity , 2018, Clinical pharmacology and therapeutics.
[60] M. Schwab,et al. The importance of drug transporter characterization to precision medicine , 2017, Expert opinion on drug metabolism & toxicology.
[61] Robert E. Stobaugh. Chemical Abstracts Service Chemical Registry System. 11. Substance-related statistics: update and additions , 1988, J. Chem. Inf. Comput. Sci..
[62] K. Giacomini,et al. The UCSF‐FDA TransPortal: A Public Drug Transporter Database , 2012, Clinical pharmacology and therapeutics.
[63] Julia M. Barbarino,et al. PharmGKB: A worldwide resource for pharmacogenomic information , 2018, Wiley interdisciplinary reviews. Systems biology and medicine.
[64] H. Parkinson,et al. A global map of human gene expression , 2010, Nature Biotechnology.
[65] Gerhard F. Ecker,et al. Prediction of drug–ABC-transporter interaction — Recent advances and future challenges☆ , 2015, Advanced drug delivery reviews.
[66] M. Hediger,et al. The ABCs of membrane transporters in health and disease (SLC series): Introduction , 2013, Molecular aspects of medicine.
[67] Saskia Preissner,et al. The Transformer database: biotransformation of xenobiotics , 2013, Nucleic Acids Res..
[68] Gang Fu,et al. PubChem Substance and Compound databases , 2015, Nucleic Acids Res..
[69] J. Schiller,et al. The alanine‐serine‐cysteine‐1 (Asc‐1) transporter controls glycine levels in the brain and is required for glycinergic inhibitory transmission , 2015, EMBO reports.
[70] David S. Goodsell,et al. RCSB Protein Data Bank: biological macromolecular structures enabling research and education in fundamental biology, biomedicine, biotechnology and energy , 2018, Nucleic Acids Res..
[71] Douglas B. Kell,et al. Implications of endogenous roles of transporters for drug discovery: hitchhiking and metabolite-likeness , 2016, Nature Reviews Drug Discovery.
[72] Gregory D. Schuler,et al. Database resources of the National Center for Biotechnology Information: update , 2004, Nucleic acids research.
[73] David S. Wishart,et al. DrugBank 5.0: a major update to the DrugBank database for 2018 , 2017, Nucleic Acids Res..
[74] K. Yanagihara,et al. Methylation status of breast cancer resistance protein detected by methylation‐specific polymerase chain reaction analysis is correlated inversely with its expression in drug‐resistant lung cancer cells , 2008, Cancer.
[75] Karryn R. Crisamore,et al. Clinical Pharmacogenomics: Applications in Nephrology. , 2018, Clinical journal of the American Society of Nephrology : CJASN.
[76] T. Aas,et al. DNA methylation profiling in doxorubicin treated primary locally advanced breast tumours identifies novel genes associated with survival and treatment response , 2010, Molecular Cancer.
[77] G. Yi,et al. HMPAS: Human Membrane Protein Analysis System , 2013, Proteome Science.